Clarithromycin
Epilepsy, Generalized
Sohag UniversitySmall moleculePhase 2/3Active
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Epilepsy, Generalized cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Topamax Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 4 | BBB |
Clobazam Lundbeck LLC | Phase 3 | BB |
Cenobamate Ono Pharmaceutical Co., Ltd. | Phase 3 | BB |
Amoxicillin Sohag University | Phase 2/3 | B |
Esomeprazole Sohag University | Phase 2/3 | B |
Diazepam Pfizer | Phase 3 | B |
Npt 2042 NeuroPro Therapeutics, Inc. | Phase 2 | CCC |
Induced pluripotent stem cells (iPSCs) University of Missouri-Columbia | D |
Same molecule, other indications
Clarithromycin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →